Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio

The transaction positions Suven as a key player in the ADC outsourcing market, which is currently valued at $2.7 billion (approx ₹22,815 crore) and projected to grow at over 25% annually.

Leave a Reply

Your email address will not be published. Required fields are marked *